$53.25+1.10 (+2.11%)
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.
Monopar Therapeutics Inc. in the Healthcare sector is trading at $53.25. The stock is currently 49% below its 52-week high of $105.00, remaining 15.2% below its 200-day moving average. Technical signals show neutral RSI of 41 and bearish MACD signal, explaining why MNPR maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNP...
Key Insights Institutions' substantial holdings in Monopar Therapeutics implies that they have significant influence...
In a welcome move, Broadcom stock saw its Relative Strength Rating improve from 70 to 79 on Monday. See if Broadcom stock can continue to show renewed price strength and clear that threshold. Is Broadcom Stock A Buy?
IONS, GPCR, MNPR and KOD more than double in 2025 as policy clarity, M&A revival and clinical wins lift biotech momentum into 2026.
Key Insights Using the 2 Stage Free Cash Flow to Equity, Monopar Therapeutics fair value estimate is US$168 Monopar...
Coinbase upgraded, Six Flags downgraded: Wall Street's top analyst calls